Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at B. Riley dropped their Q4 2025 earnings estimates for shares of Harrow in a note issued to investors on Tuesday, September 30th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of $0.55 per share for the quarter, down from their prior forecast of $0.63. B. Riley currently has a "Buy" rating and a $74.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.
Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of Harrow in a report on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. Lake Street Capital upped their price objective on shares of Harrow from $42.00 to $70.00 and gave the company a "buy" rating in a research note on Monday. Craig Hallum upped their price objective on shares of Harrow from $54.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, September 23rd. William Blair initiated coverage on shares of Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $64.00 price objective on shares of Harrow in a research note on Monday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $68.50.
Read Our Latest Analysis on Harrow
Harrow Stock Up 0.4%
HROW stock opened at $48.37 on Thursday. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23. The company's 50 day simple moving average is $39.17 and its 200-day simple moving average is $31.91. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The firm has a market capitalization of $1.79 billion, a P/E ratio of -193.48 and a beta of 0.27.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow has set its FY 2025 guidance at EPS.
Institutional Trading of Harrow
Several large investors have recently added to or reduced their stakes in HROW. Teacher Retirement System of Texas raised its stake in shares of Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company's stock valued at $259,000 after buying an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock valued at $505,000 after buying an additional 341 shares in the last quarter. Pale Fire Capital SE raised its stake in shares of Harrow by 6.8% in the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company's stock valued at $265,000 after buying an additional 550 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock valued at $483,000 after buying an additional 790 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of Harrow by 16.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 7,273 shares of the company's stock valued at $222,000 after buying an additional 1,041 shares in the last quarter. 72.76% of the stock is owned by institutional investors.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
